ArticleJACC. Advances2024
Cardiomyopathy-Associated Hospital Admissions Among Methamphetamine Users: Geographical and Social Disparities.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
- Echocardiographic characteristics of new-onset methamphetamine-associated heart failure: a retrospective cohort study.Echo research and practice · 2026Article
- Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Methamphetamine-Associated Heart Failure in the United States.Journal of the American Heart Association · 2026Article
- Modeling the Societal Impact of Methamphetamine-Associated Heart Failure.Journal of the American Heart Association · 2026Article
- Point-of-care Ultrasound for Detecting Methamphetamine-associated Heart Failure in the Emergency Department.The western journal of emergency medicine · 2026Article
- Durable LVAD therapy in end-stage methamphetamine-associated heart failure: a case report of the bridge to opportunity and transplant candidacy.European heart journal. Case reports · 2026Article
- Methamphetamine Use Among Adult Patients Presenting With Acute Coronary Syndrome: A Single-Center Retrospective Cohort Study.Journal of the American Heart Association · 2026Article
- Rural community peer partnerships for improving methamphetamine -associated heart failure screening and engagement in cardiology care (PEER-Heart): Study protocol.Drug and alcohol dependence reports · 2026Article
- Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors.Frontiers in cardiovascular medicine · 2025Article
- Community-Based Outreach for People Living With Methamphetamine-Associated Cardiomyopathy.JACC. Case reports · 2024Article
- Prevalence and patterns of methamphetamine use and mental health disparity in the United States.Nature. Mental health · 2024Article
- Home inotrope therapy in chronic stimulant-induced cardiomyopathy: a case series.European heart journal. Case reports · 2024Article
- Facing a Tsunami: Methamphetamine Heart Failure Demands Novel Approaches.JACC. Advances · 2024Article
- Health Equity Across the Life Course: A Call to Action for the Cardiovascular Community.JACC. Advances · 2024Article
- Trends in peripheral artery disease and critical limb ischemia hospitalizations among cocaine and methamphetamine users in the United States: a nationwide study.Frontiers in cardiovascular medicine · 2024Article
- Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Methamphetamine is an emerging drug threat. The disparity in cardiomyopathy-associated hospital admissions among methamphetamine users (CAHMA) over the decade remains unknown. Objectives: The purpose of this study was to determine the trends and prevalence of CAHMA by age, sex, race, and geographical region. Methods: We used data from 2008 to 2020 from the National Inpatient Sample database. We identified 12,845,919 cardiomyopathy-associated hospital admissions; among them, 222,727 were diagnosed as methamphetamine users. A generalized linear model with binomial link function was used to compute the prevalence ratio and 95% CI. Those who used other substances along with methamphetamine were excluded from the analysis. Results: CAHMA increased by 231% ( Conclusions: CAHMA have increased significantly in the United States. Men, Hispanics, non-Hispanic Asian, age groups 41 to 64. and western regions showed a higher proportional increase highlighting gender-based, racial/ethnic, and regional disparities over the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.